Phase 3, Double-Blind, Placebo-Controlled Study of Vemurafenib Versus Vemurafenib + Cobimetinib in Previously Untreated Brafv600 Mutation–Positive Patients with Unresectable Locally Advanced or Metastatic Melanoma (Nct01689519)
Grant A. McArthur(The University of Melbourne), Brigitte Dréno(Inserm), Gabriella Liszkay(National Institute of Oncology), Lev Demidov(Heidelberg University), Luis de la Cruz‐Merino, Michele Maio(University of Siena), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Stephen P. Hack, Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), James Larkin(Trinity College Dublin), Victoria Atkinson(The University of Queensland), L. Thomas, Daniil Stroyakovsky(Moscow City Oncology Hospital №62), A. Ribas, Claus Garbe(University Children's Hospital Tübingen), I‐Fen Chang(La Roche College), Mario Mandalà(University of Perugia)
Cited by 3
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k